Core Insights - The approval of "Dongyan," a hyaluronic acid compound solution, marks a significant breakthrough for the company in the medical aesthetics sector, being the first product in China to include L-carnosine for facial skin improvement [1][4][9] - The product's launch aligns with the rapid growth of the water light needle market, which is projected to reach $1.8 billion globally by 2025 and $4.5 billion in China by 2025, with a CAGR of 21.5% [4][14] Product Overview - "Dongyan" is designed to temporarily improve skin dryness and dullness, ensuring compliance and efficacy through a professional injection model [4][7] - The product features a composite formula that includes key ingredients such as hyaluronic acid, L-carnosine, vitamin B2, and essential amino acids, targeting comprehensive skin management [6][9] Market Positioning - The launch of "Dongyan" fills a gap in the market for compliant facial water light needles containing L-carnosine, which has been absent in China [5][9] - The product's positioning as a comprehensive skin improvement solution caters to the increasing demand for advanced skin health management, particularly among women over 30 [9][14] Strategic Development - The approval of "Dongyan" is part of the company's dual-engine strategy in the medical aesthetics field, complementing existing products like "Tongyan Needle" and "Shaonian Needle" [10][11] - The company has established a robust sales network covering over 6,800 medical aesthetic institutions across more than 370 cities in China, enhancing its market penetration capabilities [11][15] Financial Performance - The medical aesthetics division has shown significant growth, with a reported 85% year-on-year increase in revenue for the first half of 2025, surpassing traditional business revenue contributions [13][14] - The company is expected to continue its positive financial trajectory, supported by the launch of "Dongyan" and ongoing product development in the medical aesthetics sector [12][15]